Infection and Drug Resistance (Apr 2022)

Colistin Loading Dose in Septic Patients with Gram Negative Infections

  • Alshaya AI,
  • Bin Saleh K,
  • Aldhaeefi M,
  • Baderldin HA,
  • Alamody FO,
  • Alhamdan QA,
  • Almusallam MA,
  • Alshaya O,
  • Al Sulaiman K,
  • Alshareef S,
  • Alowais SA,
  • Al Harbi SA,
  • Alghamdi G

Journal volume & issue
Vol. Volume 15
pp. 2159 – 2166

Abstract

Read online

Abdulrahman I Alshaya,1– 3 Khalid Bin Saleh,1– 3 Mohammed Aldhaeefi,1– 3 Hisham A Baderldin,1– 3 Farris O Alamody,1 Qusai A Alhamdan,1 Mohammed A Almusallam,1 Omar Alshaya,1– 3 Khalid Al Sulaiman,1– 3 Shaima Alshareef,3 Shuroug A Alowais,1– 3 Shmeylan A Al Harbi,1– 3 Ghassan Alghamdi2,4 1College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 2King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 3Department of Pharmaceutical Care Services, King Abdulaziz Medical City, Riyadh, Saudi Arabia; 4College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaCorrespondence: Abdulrahman I Alshaya, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia, Email [email protected]: Intravenous (IV) colistin is commonly used to treat multidrug-resistant gram-negative infections. It is primarily eliminated renally and may induce acute kidney injury (AKI) at a rate of up to 53%. Consequently, septic patients who require colistin administration have an additional risk of developing AKI. The aim of this study is to investigate clinical failure and AKI predictors for septic patients treated with IV colistin.Methods: This retrospective cohort study was conducted at a tertiary teaching hospital in Saudi Arabia. Adult septic patients with suspected or confirmed gram-negative infections who received colistin admitted to the hospital between May 2016 and December 2020 were screened after obtaining IRB approval. AKI was defined based on the AKI Network criteria. We investigated the incidence of clinical failure based on colistin dosing and AKI risk factors, such as the development of septic shock, severity of illness, and medication co-administration using a multiple logistic regression model.Results: After screening 163 patients, 103 patients were included in the analysis. No difference was observed between the colistin dosing strategies for clinical failure. Of the included predictors, development of septic shock (OR: 3.75; 95% CI 1.18– 13.15), carbapenem co-administration (OR, 3.96; 95% CI, 1.134– 15.57) were associated with an increased risk of AKI. The other factors were not significant predictors.Conclusion: Clinical failure was not affected by colistin dosing strategies in our cohort of patients with sepsis. Moreover, the co-administration of carbapenems and the development of septic shock may increase the risk of inducing AKI in adult septic patients treated with IV colistin. Further studies are required to confirm these findings.Keywords: sepsis, infection, colistin, loading dose, gram-negative, renal failure

Keywords